Supernus Pharmaceuticals Reports Q1 2025 Earnings Growth

Supernus Pharmaceuticals ( (SUPN) ) has released its Q1 earnings. Here is a breakdown of the information Supernus Pharmaceuticals presented to its investors.

Supernus Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for central nervous system diseases, with a diverse portfolio that includes products for ADHD, Parkinson’s disease, epilepsy, and more.

In its first quarter of 2025, Supernus Pharmaceuticals reported a notable increase in net sales for its key products, Qelbree and GOCOVRI, contributing to a 4% rise in total revenues compared to the same period in 2024. The company also successfully launched ONAPGO, a new treatment for Parkinson’s disease, in the U.S.

The company’s financial performance showed mixed results, with a 44% increase in net sales of Qelbree and a 16% rise in GOCOVRI sales. However, the overall operating loss widened to $10.3 million, primarily due to increased marketing expenses and contingent consideration losses. Despite this, adjusted operating earnings improved by 16% to $25.9 million.

Supernus continues to advance its product pipeline with ongoing clinical trials for new treatments targeting epilepsy and depression. The company maintains a strong cash position, with $463.6 million in cash and marketable securities, supporting its strategic initiatives and product development.

Looking ahead, Supernus Pharmaceuticals remains committed to achieving its full-year financial guidance for 2025, focusing on revenue growth and expanding its market presence with new and existing products.